Clinical Trial Update: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

The document describes a Phase 1 neoadjuvant trial of cemiplimab (Libtayo) for Merkel cell carcinoma and locoregionally advanced cutaneous squamous cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Merkel Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING